...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study
【24h】

Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study

机译：多日帕洛诺司琼与阿瑞匹坦和小剂量地塞米松联合使用预防自体造血干细胞移植的多发性骨髓瘤和淋巴瘤患者恶心和呕吐的初步研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The current standard for prevention of chemotherapy-induced nausea/vomiting in autologous stem cell transplant only achieves 4-20% emetic control. Objectives: To assess emetic responses to multiday palonosetron, aprepitant, and low-dose dexamethasone among patients with myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant. Methods: Oral aprepitant 125/80/80 mg was administered with intravenous dexamethasone 4 mg and palonosetron 0.25 mg on days -3, -2, -1 for multiple myeloma and days -7 through -3 for lymphoma. Palonosetron was repeated day +3 in both groups. Results: A total of 20 patients were enrolled and 18 analyzed. None experienced emetic failure with complete control achieved in 78, 33, and 17% in the acute, delayed, and extended phases, respectively. Nausea occurred in 78% although not significant in 61%, with median Nausea Visual Score of 4.5. Quality of life correlated with emetic and nausea control. Eight patients developed grade 2-3 nonhematologic toxicities with only one event attributed to the study medications. Conclusions: This triplet regimen was feasible with acceptable safety profile in the autologous hematopoietic stem cell transplant setting. Emetic control was best achieved in the acute phase. Lesser degree of emetic and nausea control in the delayed and extended phases impacted quality of life. Our results warrant further evaluation in a larger autologous hematopoietic stem cell transplant population.
机译：背景：目前预防自体干细胞移植中化学疗法引起的恶心/呕吐的标准仅能达到4-20％的催吐控制。目的：评估接受自体造血干细胞移植的骨髓瘤和淋巴瘤患者对帕洛诺司琼，阿瑞匹坦和小剂量地塞米松的催吐反应。方法：在多发性骨髓瘤的第-3，-2，-1天和淋巴瘤的第-7天至第-3天，分别向口服瑞芬坦125/80/80 mg，地塞米松4 mg和帕洛诺司琼0.25 mg。两组均在第3天重复Palonosetron。结果：总共招募了20位患者，并对18位患者进行了分析。在急性期，延迟期和延长期，没有人出现催吐失败，完全控制率分别达到78％，33％和17％。恶心发生率为78％，但不显着为61％，恶心视觉评分中位数为4.5。生活质量与呕吐和恶心控制有关。 8名患者出现2-3级非血液学毒性，只有一种事件归因于研究药物。结论：这种三联体方案在自体造血干细胞移植环境中可行，安全性可接受。在急性期最好达到催吐控制。延迟和延长阶段的催吐和恶心控制程度较低，影响了生活质量。我们的结果值得在更大的自体造血干细胞移植人群中进行进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号